SOURCE: NeuroInvestment

September 04, 2007 13:19 ET

/ CORRECTION - Alzheimer's Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - September 4, 2007) - In the news release, "Alzheimer's Therapeutics Reviewed by NeuroInvestment," issued earlier today by NeuroInvestment, we are advised by the company that the email address included in the contact information of the release should read rather than as originally issued. Complete corrected text follows.

Alzheimer's Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA -- September 4, 2007 -- NI Research has released the September issue of NeuroInvestment, which reviews the current status and prospects of treatments for Alzheimer's, the disorder whose burgeoning patient population threatens to overwhelm our health care system within the next two decades unless effective therapeutics are developed. One recent estimate is that delaying the onset of Alzheimer's by five years would save the American health system almost $4 trillion by mid-century. Current drug options offer only temporary improvement for a minority of patients.

This review assesses the current state of the science regarding the pathophysiology of Alzheimer's, including contributory factors such as amyloid, tau, cholesterol, oxidants, and inflammation. The main body of the review asesses coming generations of treatments for Alzheimer's, including numerous approaches to amyloid pathology, tau, metal chelation, neuroprotection, and others. Companies whose programs are in this review include:

Abbott, Accera, AC Immune, Allon Therapeutics, American Life Sciences Pharmaceuticals, Armagen, AstraZeneca, Boehringer Ingelheim, Ceregene, CoMentis, Cortex Pharmaceuticals, D-Pharm, Elan, Elbion, EnVivo Pharmaceuticals, Epix, Evotec, GlaxoSmithKline, Hunter-Fleming, Intellect Neuroscience, Key Neurotek, Kinexis, Lilly, Lundbeck, Medeia Therapeutics, Memory Pharmaceuticals, Merck, Myriad Genetics, Neuro-Hitech, Neurochem, Novartis, NsGene, Ono, Pfizer, Prana, Roche, Sanofi-Aventis, Senexis, Synosia Therapeutics, Targacept (NASDAQ: TRGT), Torrey Pines Therapeutics (NASDAQ: TPTX), Transition Therapeutics, UCB Pharma, Voyager, and Wyeth.

The September issue of NeuroInvestment also takes a close look at such topics as Neurochem's dilemma in the wake of Phase III failure; the intelligent partnering template established by Targacept and GSK, and the underpinnings of Samaritan Pharmaceuticals. There is also a focus review of Cortex Pharmaceuticals (AMEX: COR).

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $1500, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three month trial subscription is US$500. Due to the high interest in this topic area, the September Alzheimer's review issue will also be made available on a single-issue basis, for $300.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and has added CNS 2007-8. an annual compendium of all neuro-oriented R&D programs organized by disorder. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

Contact Information